Table 2.

ROC analysis of the diagnostic efficiency of differential long non-coding ribonucleic acids (lncRNAs) (RP11-33A14.1, RP11-423H2.3, and LAMTOR5-AS1) and serum prostate-specific antigen (PSA) in prostate cancer (PCa) patients and benign prostatic hyperplasia (BPH) controls.

Biomarker	Sensitivity (%)	Specificity (%)	AUC (95% CI)	P-value
RP11-33A14.1	60.4	70.2	0.697 (0.506–0.734)	0.001
RP11-423H2.3	56.2	61.4	0.620 (0.506–0.734)	0.035
LAMTOR5-AS1	58.3	64.9	0.641 (0.531–0.751)	0.013
LAMTOR5-AS1 + RP11-33A14.1+RP11-423H2.3	77.1	63.2	0.754 (0.655–0.854)	<0.001
PSA	95.8	84.2	0.974 (0.946–0.998)	<0.001
LAMTOR5-AS1 + RP11-33A14.1+RP11-423H2.3 + PSA	97.9	84.2	0.984 (0.964–1.004)	<0.001